[
    {
        "EligibilityCriteria": "Inclusion Criteria:\n\n* One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors:\n\n  * Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix\n  * Endometrial cancer\n  * Head and neck squamous cell carcinoma (HNSCC)\n  * Unresectable biliary adenocarcinoma (gallbladder or biliary tree \\[intrahepatic or extrahepatic\\] cholangiocarcinoma)\n  * Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).\n  * Triple-negative breast cancer (TNBC)\n  * Hepatocellular carcinoma (HCC)\n  * Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra\n  * Ovarian cancer\n  * Gastric cancer\n* Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.\n* Adequately controlled blood pressure (BP) with or without antihypertensive medications.\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).\n* Male participants must agree to follow contraceptive guidance.\n* Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.\n* Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.\n* Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Active infection requiring systemic therapy.\n* Concurrent active hepatitis B and hepatitis C virus infection.\n* History of allogenic tissue/solid organ transplant.\n* Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).\n* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.",
        "InclusionCriteria": "* One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors:\n\n  * Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix\n  * Endometrial cancer\n  * Head and neck squamous cell carcinoma (HNSCC)\n  * Unresectable biliary adenocarcinoma (gallbladder or biliary tree \\[intrahepatic or extrahepatic\\] cholangiocarcinoma)\n  * Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).\n  * Triple-negative breast cancer (TNBC)\n  * Hepatocellular carcinoma (HCC)\n  * Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra\n  * Ovarian cancer\n  * Gastric cancer\n* Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.\n* Adequately controlled blood pressure (BP) with or without antihypertensive medications.\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).\n* Male participants must agree to follow contraceptive guidance.\n* Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.\n* Adequate organ function.",
        "ExclusionCriteria": "* History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.\n* Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.\n* Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Active infection requiring systemic therapy.\n* Concurrent active hepatitis B and hepatitis C virus infection.\n* History of allogenic tissue/solid organ transplant.\n* Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).\n* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.",
        "HealthyVolunteers": false,
        "Gender": "ALL",
        "MinimumAge": "18 Years",
        "NCTId": "NCT05007106",
        "startDate": "",
        "completionDate": "",
        "durationDays": null,
        "daysUntilEnd": null
    }
]